Ovid Therapeutics (OVID) Non Operating Income (2016 - 2020)

Ovid Therapeutics (OVID) has reported Non Operating Income for 5 consecutive years, with $590491.0 the latest figure, recorded in Q2 2020.

• For the quarter ending Q2 2020, Non Operating Income rose 122.83% year-over-year to $590491.0; the trailing twelve-month figure through Jun 2020 stood at $1.3 million (up 35.48% YoY), and the FY2019 full-year result was $948224.0, changed 0.4% from the prior year.
• Non Operating Income climbed to $590491.0 in Q2 2020 per OVID's latest filing, from $264296.0 in the prior quarter.
• Across five years, Non Operating Income topped out at $590491.0 in Q2 2020 and bottomed at $23000.0 in Q1 2017.
• Historically, Non Operating Income has averaged $170951.4 across 5 years, with a median of $172500.0 in 2018.
• The sharpest annual moves came in 2018 and 2019: Non Operating Income soared 973.91% in 2018, then slumped 38.79% in 2019.
• Over 5 years, Non Operating Income stood at $27000.0 in 2016, then jumped by 225.93% to $88000.0 in 2017, then surged by 145.45% to $216000.0 in 2018, then jumped by 38.43% to $299000.0 in 2019, then surged by 97.49% to $590491.0 in 2020.
• According to Business Quant data, Non Operating Income over the past three periods registered $590491.0, $264296.0, and $299000.0 for Q2 2020, Q1 2020, and Q4 2019 respectively.